----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Clin Cancer Res. 2018 Nov 16;:
Authors: Choi BD, Maus MV, June CH, Sampson JH
Abstract
Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immune therapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CARs), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anti-cancer therapy will ultimately work for brain tumors, and if the primary immunologic challenges in this disease-which include antigenic heterogeneity, immune suppression and T-cell exhaustion-can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.
PMID: 30446589 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - November 16, 2018 Category: Cancer & Oncology Authors: Choi BD, Maus MV, June CH, Sampson JH Tags: Clin Cancer Res Source Type: research